rAAV2-PCBP1-EGFP

**rAAV2-PCBP1-EGFP** is an experimental **AAV2-based gene therapy** research construct designed to deliver and express **poly(rC)-binding protein 1** together with the reporter **enhanced green fluorescent protein** in target cells. Based on the cited Parkinson's disease preclinical study, it was used as a recombinant viral vector to increase PCBP1 expression and evaluate whether PCBP1-mediated pathways can protect dopaminergic neurons in a **6-hydroxydopamine lesion model of Parkinson's disease**. It appears to be an academic, preclinical investigational gene-transfer tool rather than a named commercial drug product, with activity driven by transgene expression after local administration to the nervous system.

Other names

recombinant adeno-associated virus serotype 2 encoding PCBP1 and EGFPAAV2-PCBP1-EGFPAAV-2-PCBP1-EGFPAAV 2-PCBP1-EGFP